[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Submit :: Indexing :: Contact Us ::
:: Volume 12, Issue 4 (11-2022) ::
JABS 2022, 12(4): 378-387 Back to browse issues page
Hsa-miR-662 as a New Prognostic Biomarker in Patients with Breast Cancer; In-silico and Experimental Study
Zahra Foruzandeh1 , Mohammad Reza Alivand * 2, Mehdi Ghiami Rad3 , Mohammad Zaefizadeh4 , Saeid Ghorbian1
1- Department of Molecular Genetics, Ahar Branch, Islamic Azad University, Ahar, Iran
2- Eye Research Center, the Five Senses Health Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran , mohammadreza_alivand@yahoo.com
3- Department of Microbiology, Faculty of Basic Sciences, Ahar Branch, Islamic Azad University, Ahar, Iran
4- Department of Biology, Faculty of Sciences, Ardabil Branch, Islamic Azad University, Ardabil, Iran
Abstract:   (71 Views)
Background & Objective: Breast cancer (BC) is a complex genetic disease that has an average annual incidence of one million people and is the second leading cause of death among women in the world. Therefore, a better understanding of tumor biology and the determination of biomarkers for early diagnosis of disease is essential. MicroRNAs and long non-coding RNAs are novel gene regulators that play key roles in tumor initiation and progression. The current study was performed to assess the biomarker potential. This study performed a combination of in-silico and experimental investigations of altered miRNAs in BC to assess the use of miRNAs as novel biomarkers for early detection and prognosis prediction of patients with BC.
Materials & Methods: We searched the miRNA expression patterns of BC from three expression arrays (GSE58606, GSE38867, and GSE40525,) from the Gene Expression Omnibus (GEO) database to recognize differentially expressed miRNAs (DEMs) between BC tissues and normal adjacent samples. Using “Limma" package's Quantile Normalization function and INMEX bioinformatic tool, hub DEMs were identified. MiRNAs targeted genes were found and visualized via the miRWalk and miRTargetLink databases and their Enrichment analysis was performed for identified genes. Due to more validation of DEGs, GSE70951, an independent expression array dataset, was analyzed. By merging DEMs and DEGs, miRNA-mRNA network was constructed. After elucidation of hub miRNAs, the capacity of detected miRNAs to differentiate BC from adjacent controls was estimated by Kaplan-Meier analysis.  Furthermore, RT-qPCR on 100 BC samples and 100 adjacent non-tumor tissues was performed to validate the in-silico results.
Results: According to our study, in BC samples, miR-662 was differentially downregulated in comparison with normal adjacent tissues.
Conclusion: Altogether, miR-662 can be considered as a viable target for BC diagnostics and treatment.
Keywords: Breast Cancer, MicroRNA, Hsa-miR-662, Prognosis
Full-Text [PDF 990 kb]   (27 Downloads)    
Type of Study: Research | Subject: Medical Genetics
Received: 2022/07/30 | Accepted: 2022/09/21 | Published: 2022/12/28
Send email to the article author

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Foruzandeh Z, Alivand M R, Ghiami Rad M, Zaefizadeh M, Ghorbian S. Hsa-miR-662 as a New Prognostic Biomarker in Patients with Breast Cancer; In-silico and Experimental Study. JABS 2022; 12 (4) :378-387
URL: http://jabs.fums.ac.ir/article-1-2883-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 12, Issue 4 (11-2022) Back to browse issues page
Journal of Advanced Biomedical Sciences
Persian site map - English site map - Created in 0.04 seconds with 29 queries by YEKTAWEB 4540
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0)